•   SABRINA is an open label, multicenter, single arm, phase II study, enrolled 93 BRCA1/2 mutated recurrent platinum-sensitive non-         mucinous epithelial ovarian cancer patients with at least 2 lines of prior systemic treatment (Data cutoff: 2024.12.17).

 • The median age of patients was 55, and 62% had 6-12 months of last platinum free interval, with a median 2 lines of prior systemic        therapies.

 • As assessed by IRC, ORR was 66.3%, median PFS was 11.14 months and median DOR was 10.35 months. The median OS was 42.45          months.

 •The common TRAEs were anemia, white blood cell count decreased, platelet count decreased, neutrophil count decreased, and nausea.

Founded in 2009, IMPACT Therapeutics is a commercial-stage, innovation-driven biotechnology company focused on advancing synthetic lethality (SL)-based precision anti-cancer therapies globally to redefine standard of care. We have discovered and developed one of the most comprehensive and advanced SL franchises and are one of only three companies with both commercial-stage PARP1/2 inhibitors and clinical-stage next-generation PARP1 selective inhibitors worldwide. We have commercialized our Core Product, senaparib, in China as a 1L maintenance therapy for ovarian cancer (OC) across all patient populations regardless of mutation status and demonstrating a best-in-class clinical profile. Our continued growth is powered by an integrated R&D platform that enables innovation across both small molecules and emerging modalities, including next-generation antibody-drug conjugates (ADCs) and degraders. Additionally, we have forged partnerships with leading global biotech and China pharmaceutical companies to date, as validation of our pipeline and R&D platform.

IMPACT’s major clinical pipeline drug candidates include the PARP1/2 inhibitor Senaparib (IMP4297), PARP1 selective inhibitors (IMP1734 and IMP1707, co-developed with Eikon Therapeutics), ATR inhibitor (IMP9064), Wee1 inhibitor (IMP7068), and multiple other synthetic lethality target inhibitors.

For additional information, please visit  www.impacttherapeutics.com

IMPACT Therapeutics Contact:

+86 21 6841 1121

IR@impacttherapeutics.com

PR@impacttherapeutics.com